Onconetix (ONCO) Change in Accured Expenses (2021 - 2026)
Onconetix (ONCO) posted quarterly Change in Accured Expenses of -$62543.0 for Q1 2026, down 123.18% year-over-year from $269779.0 in Q1 2025, and up 56.0% quarter-over-quarter from -$142150.0 in Q4 2025.
Onconetix (ONCO) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Change in Accured Expenses for 6 consecutive years, with -$62543.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 123.18% year-over-year to -$62543.0; the TTM figure through Mar 2026 stood at -$912354.0 (down 52.58% YoY), while the FY2025 annual figure was -$580032.0, up 48.63% from the prior year.
- Change in Accured Expenses rose to -$62543.0 in Q1 2026 per ONCO's latest filing, from -$142150.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.5 million in Q3 2022 and bottomed at -$1.0 million in Q4 2022.
- Historically, Change in Accured Expenses has averaged -$57285.4 across 5 years, with a median of -$142150.0 in 2025.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 2404.07% — and 2024, when it tumbled 1542.42%.
- Onconetix's Change in Accured Expenses stood at -$1.0 million in 2022, then surged by 103.41% to $34796.0 in 2023, then slumped by 261.71% to -$56269.0 in 2024, then sank by 152.63% to -$142150.0 in 2025, then surged by 56.0% to -$62543.0 in 2026.
- Business Quant data shows ONCO's Change in Accured Expenses at -$62543.0 in Q1 2026, -$142150.0 in Q4 2025, and -$427930.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | -28,548.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28,548.00 |
| Jun 30, 2026 | -28,548.00 |
| Mar 31, 2026 | -62,543.00 |
| Mar 31, 2026 | -62,543.00 |
| Dec 31, 2025 | -142,150.00 |
| Dec 31, 2025 | -142,150.00 |
| Sep 30, 2025 | -427,930.00 |
| Sep 30, 2025 | -427,930.00 |
| Jun 30, 2025 | -279,731.00 |
| Jun 30, 2025 | -279,731.00 |
| Mar 31, 2025 | 269,779.00 |
| Mar 31, 2025 | 269,779.00 |
| Dec 31, 2024 | -56,269.00 |
| Dec 31, 2024 | -56,269.00 |
| Sep 30, 2024 | -179,553.00 |
| Sep 30, 2024 | -179,553.00 |
| Jun 30, 2024 | -631,925.00 |
| Jun 30, 2024 | -631,925.00 |
| Mar 31, 2024 | -261,303.00 |
| Mar 31, 2024 | -261,303.00 |